Nanobiotix S.A.
Close on Oct 19, 2026
About Nanobiotix
Pharmaceutical Preparations, SIC 2834
Nanobiotix S.A. is a clinical-stage biotechnology company that develops physics-based nanotherapeutics designed to treat cancer and other diseases. The company operates through three main technology platforms: a nanoradioenhancer platform, a nanoprimer platform, and a neurological disease platform. Its lead product candidate, JNJ-1900 (also known as NBTXR3), is an intratumorally injected suspension of hafnium oxide nanoparticles designed to amplify the tumor-destroying effect of radiation therapy in solid tumors, including head and neck and lung cancers. The company serves cancer patients requiring radiotherapy, collaborating with pharmaceutical corporations and medical research institutions to conduct clinical evaluations and commercialization.
The company is headquartered in Paris, France, where its research, development, and manufacturing facilities are located. It also maintains corporate operations in Cambridge, Massachusetts. Its clinical research activities and collaborative trial programs include investigator sites and patient populations across Europe, Asia, and the United States.
Summary of the business section of Nanobiotix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nanobiotix S.A.
- Founded
- 2003
- Headquarters
- Paris, I0
- Address
- 60 Rue De Wattignies 75012
- Phone
- 33140260470
- Website
- nanobiotix.com
- Employees
- 97, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young et Autres, Paris-La Defense, France
Stock & identifiers
- Ticker
- NBTX
- Other tickers
- NNBXF
- Exchange
- Nasdaq
- IPO date
- Dec 11, 2020
- Shares outstanding
- 48M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1760854
- CUSIP
- 63009J107
- ISIN
- US63009J1079
- LEI
- 969500667RSYIH8YL895
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Nanobiotix's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“At December 31, 2025, our workforce totaled 97 employees, a decrease of 11 positions as compared to the same period in 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 11, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 8, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |